• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.使用非氯化推进剂HFA134a的沙美特罗吸入器：健康志愿者的全身药效学活性
Thorax. 1995 Jun;50(6):679-81. doi: 10.1136/thx.50.6.679.
2
Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.健康受试者中使用含氯氟烃推进剂和不含氯氟烃推进剂的定量吸入器递送沙美特罗的全身药效学效应和药代动力学比较。
Respir Med. 2005 Apr;99 Suppl A:S11-9. doi: 10.1016/j.rmed.2004.11.005. Epub 2005 Jan 18.
3
Clinical evaluation of CFC-free metered dose inhalers.不含氯氟烃的定量吸入器的临床评估。
J Aerosol Med. 1995 Spring;8 Suppl 1:S41-7. doi: 10.1089/jam.1995.8.suppl_1.s-41.
4
Clinical pharmacology of HFA134a.
J Aerosol Med. 1995 Spring;8 Suppl 1:S35-9. doi: 10.1089/jam.1995.8.suppl_1.s-35.
5
Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.沙美特罗与丙酸氟替卡松联合给药。缺乏全身药效学和药代动力学相互作用。
Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):781-91. doi: 10.1007/s002280000233.
6
Therapeutic equivalence of a novel HFA134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma.一种新型含氢氟烷烃134a的定量吸入器与传统含氯氟烃吸入器（贝罗都尔）用于递送非诺特罗/异丙托溴铵固定组合的治疗等效性。一项针对哮喘患者的随机双盲安慰剂对照交叉研究。
Respiration. 1997;64(4):273-80. doi: 10.1159/000196686.
7
Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life.丙酸氟替卡松和沙美特罗氢氟烷吸入气雾剂对哮喘相关生活质量的影响。
Ann Allergy Asthma Immunol. 2009 Apr;102(4):323-7. doi: 10.1016/S1081-1206(10)60338-9.
8
Acute safety of the CFC-free propellant HFA-134a from a pressurized metered dose inhaler.来自定量压力气雾剂的无氯氟烃推进剂HFA-134a的急性安全性。
Eur J Clin Pharmacol. 1995;48(6):473-7. doi: 10.1007/BF00194337.
9
Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects.健康受试者中沙美特罗和沙丁胺醇全身效应的时间过程和相对剂量效价。
Thorax. 1997 May;52(5):458-64. doi: 10.1136/thx.52.5.458.
10
Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.丙酸氟替卡松和沙美特罗联合干粉吸入剂（胶囊型和多剂量型）在哮喘和 COPD 患者中的药代动力学和药效学。
J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):279-89. doi: 10.1089/jamp.2013.1040. Epub 2013 Sep 28.

引用本文的文献

1
Fluticasone Induces Epithelial Injury and Alters Barrier Function in Normal Subjects.氟替卡松可导致正常受试者的上皮损伤并改变屏障功能。
J Steroids Horm Sci. 2014 Jun 11;5(2). doi: 10.4172/2157-7536.1000134.
2
Regular treatment with salmeterol for chronic asthma: serious adverse events.沙美特罗用于慢性哮喘的常规治疗：严重不良事件
Cochrane Database Syst Rev. 2008 Jul 16;2008(3):CD006363. doi: 10.1002/14651858.CD006363.pub2.

本文引用的文献

1
Salmeterol: an inhaled beta 2-agonist with prolonged duration of action.沙美特罗：一种吸入性长效β2受体激动剂。
Lung. 1993;171(5):249-64. doi: 10.1007/BF03215869.
2
Dose-response study with high-dose inhaled salmeterol in healthy subjects.健康受试者高剂量吸入沙美特罗的剂量反应研究。
Br J Clin Pharmacol. 1992 Mar;33(3):342-5. doi: 10.1111/j.1365-2125.1992.tb04049.x.

使用非氯化推进剂HFA134a的沙美特罗吸入器：健康志愿者的全身药效学活性

Salmeterol inhaler using a non-chlorinated propellant, HFA134a: systemic pharmacodynamic activity in healthy volunteers.

作者信息

Kirby S M, Smith J, Ventresca G P

机构信息

Clinical Pharmacology Division, Glaxo Research and Development Ltd, Greenford, Middlesex, UK.

出版信息

Thorax. 1995 Jun;50(6):679-81. doi: 10.1136/thx.50.6.679.

DOI:10.1136/thx.50.6.679
PMID:7638815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1021273/
Abstract

BACKGROUND

Metered dose inhalers for the treatment of asthma use chlorofluorocarbons as propellants. These face an international ban due to their effect on the ozone layer. Salmeterol has been reformulated using the non-chlorinated propellant Glaxo inhalation grade HFA134a.

METHODS

The safety, tolerability and systemic pharmacodynamic activity of the salmeterol/HFA134a inhaler, the current salmeterol inhaler, and placebo (HFA134a) were compared in 12 healthy volunteers in a double blind, randomised crossover study using a cumulative dosing design.

RESULTS

Safety and tolerability were similar and the response was related to the dose over the range used (50-400 micrograms) with both salmeterol inhalers. The salmeterol/HFA134a inhaler showed no differences from the current inhaler for pulse rate, blood pressure, tremor, QTc interval, and plasma glucose levels. The salmeterol/HFA134a inhaler had significantly less effect on plasma potassium levels.

CONCLUSIONS

In healthy volunteers the salmeterol/HFA134a inhaler is at least as safe and well tolerated as the current salmeterol inhaler, and has similar systemic pharmacodynamic activity.

摘要

背景

用于治疗哮喘的定量吸入器使用氯氟烃作为推进剂。由于它们对臭氧层的影响，这些推进剂面临国际禁令。沙美特罗已重新配方，使用了非氯化推进剂葛兰素吸入级HFA134a。

方法

在一项采用累积给药设计的双盲、随机交叉研究中，对12名健康志愿者比较了沙美特罗/HFA134a吸入器、当前的沙美特罗吸入器和安慰剂（HFA134a）的安全性、耐受性和全身药效学活性。

结果

两种沙美特罗吸入器的安全性和耐受性相似，在所使用的剂量范围（50 - 400微克）内，反应与剂量相关。沙美特罗/HFA134a吸入器在脉搏率、血压、震颤、QTc间期和血浆葡萄糖水平方面与当前吸入器无差异。沙美特罗/HFA134a吸入器对血浆钾水平的影响明显较小。

结论

在健康志愿者中，沙美特罗/HFA134a吸入器至少与当前的沙美特罗吸入器一样安全且耐受性良好，并且具有相似的全身药效学活性。